Regulatory News Exercising new powers, FDA issues Complete Response Letters based on insufficient enrollment in confirmatory trials March 29, 2024Vol.50 No.13By Paul Goldberg
Daniel Snyder, former Washington Commanders owner, donates riverfront “château” to ACS March 29, 2024Vol.50 No.13By Jacquelyn Cobb
FreeIn the Archives Women’s History Month—How “Dr. Susan Love’s Breast Book” has remained the “bible” for women with breast cancer since 1990 March 29, 2024Vol.50 No.13By Alexandria Carolan
Regulatory News ODAC votes in favor of two CAR T-cell therapies for MM after weighing FDA concerns about early deaths March 22, 2024Vol.50 No.12By Jacquelyn Cobb and Paul Goldberg
NCI Rathmell announces new cancer screening network, new NCI virtual clinical trials office March 22, 2024Vol.50 No.12By Matthew Bin Han Ong
U.S., Sweden sign cancer research and innovation pact as part of preparedness plan for potential Russian aggression March 22, 2024Vol.50 No.12By Matthew Bin Han Ong
Cancer History ProjectConversation with The Cancer LetterFree Weeks before death from sarcoma, Norm Coleman reflected on his career in radiation oncology and addressing health disparities March 22, 2024Vol.50 No.12By Otis W. Brawley, Alexandria Carolan and Paul Goldberg
FreeGuest Editorial The global health contributions of Norm Coleman March 22, 2024Vol.50 No.12By Nina Wendling and Donna M. O’Brien
Conversation with The Cancer LetterRegulatory News FDA’s Harpreet Singh: Overall survival data tells the full story of immune checkpoint inhibitor benefit in NSCLCPooled analysis finds correlations between early endpoints and OS in ICI trials March 15, 2024Vol.50 No.11By Matthew Bin Han Ong and Paul Goldberg
